KEY MEMBERS
NeoImmuneTech (NIT) is led by a highly experienced team of scientific, clinical, business, operational and financial experts, relentlessly pursuing the development of novel cancer and immune therapies.
Se Hwan Yang, Ph.D. - President / Chief Executive Officer
Dr. Se Hwan Yang founded NeoImmuneTech in January 2014. Dr. Yang has created several intellectual-property protected inventions, including the hyFc® platform technology and NT-I7 drug candidate. Prior to his position at NIT, Dr. Yang was Genexine’s Head of Research Institute and Business Division from 2007 to 2014 and has served as a BOD member of Genexine. He received his Ph.D. from Pohang University of Science and Technology and has over 20 years of experience in research, product development and business in life sciences, including molecular biology, immunology and protein engineering.
Dr. Se Hwan Yang founded NeoImmuneTech in January 2014. Dr. Yang has created several intellectual-property protected inventions, including the hyFc® platform technology and NT-I7 drug candidate. Prior to his position at NIT, Dr. Yang was Genexine’s Head of Research Institute and Business Division from 2007 to 2014 and has served as a BOD member of Genexine. He received his Ph.D. from Pohang University of Science and Technology and has over 20 years of experience in research, product development and business in life sciences, including molecular biology, immunology and protein engineering.
Byung Ha Lee, Ph.D. - Chief Scientific Officer
Dr. Lee has extensive scientific expertise, with over 15 years of diverse drug development experience. He joined NIT in 2016 as a Principal Scientist and later moved into the Director of R&D position in 2019, followed by the appointment to CSO in 2021. Dr. Lee has been an integral member of the scientific team, leading the development of comprehensive pre-clinical and biomarker strategies for NT-I7 (efineptakin alfa) which has resulted in the strong scientific merit of the asset to date. Prior to joining NIT, Dr. Lee held various research leadership positions in the biotechnology space, including served as Project Leader at Samsung Biomedical Research Institute and Project Leader / Strategy Planning & Transactions at Genexine. Dr. Lee earned his Ph.D. degree in Medical Sciences in Immunology and Microbiology from the University of Florida, College of Medicine, and completed his post-doc at NIH/NIAID.
Dr. Lee has extensive scientific expertise, with over 15 years of diverse drug development experience. He joined NIT in 2016 as a Principal Scientist and later moved into the Director of R&D position in 2019, followed by the appointment to CSO in 2021. Dr. Lee has been an integral member of the scientific team, leading the development of comprehensive pre-clinical and biomarker strategies for NT-I7 (efineptakin alfa) which has resulted in the strong scientific merit of the asset to date. Prior to joining NIT, Dr. Lee held various research leadership positions in the biotechnology space, including served as Project Leader at Samsung Biomedical Research Institute and Project Leader / Strategy Planning & Transactions at Genexine. Dr. Lee earned his Ph.D. degree in Medical Sciences in Immunology and Microbiology from the University of Florida, College of Medicine, and completed his post-doc at NIH/NIAID.
Gene Namgoong, J.D. - Chief Operating Officer
Mr. Namgoong joined NeoImmuneTech in 2014 as a legal advisor, later assuming the critical role of General Counsel in 2016. As NeoImmuneTech’s General Counsel, he held a range of responsibilities including advising management, the board, and company on key legal matters, as well as played an instrumental role in supporting the CEO with company operations at NeoImmuneTech’s U.S. Headquarters. Prior to joining NeoImmuneTech, Mr. Namgoong served as a legal advisor for JK BioPharma Solutions, Inc., a Maryland-based biotech company where he acquired extensive knowledge in the field of biotechnology. In addition, he worked at several law firms focusing on representing international businesses seeking to operate in the U.S. Mr. Namgoong holds a J.D. from Syracuse University College of Law and a B.A. in Government from the University of Texas at Austin.
Mr. Namgoong joined NeoImmuneTech in 2014 as a legal advisor, later assuming the critical role of General Counsel in 2016. As NeoImmuneTech’s General Counsel, he held a range of responsibilities including advising management, the board, and company on key legal matters, as well as played an instrumental role in supporting the CEO with company operations at NeoImmuneTech’s U.S. Headquarters. Prior to joining NeoImmuneTech, Mr. Namgoong served as a legal advisor for JK BioPharma Solutions, Inc., a Maryland-based biotech company where he acquired extensive knowledge in the field of biotechnology. In addition, he worked at several law firms focusing on representing international businesses seeking to operate in the U.S. Mr. Namgoong holds a J.D. from Syracuse University College of Law and a B.A. in Government from the University of Texas at Austin.
Tae Woo Kim, CPA - Chief Financial Officer
Mr. Kim joined NeoImmuneTech, Inc. in May 2018 as Finance Director. His professional career began at PricewaterhouseCoopers (PwC) Korea in 2006. For 10+ years at PwC, he was mainly involved with financial audit services for Korean listed companies as a part of the Capital Market Group. Also, during his period at PwC, he successfully completed his secondment to another PwC territory, PwC Taiwan, for three years. This greatly increased his knowledge of Korean Capital Markets and overall global acumen. After that, he joined Englewood Lab, a New Jersey based company, and third US company listed on KOSDAQ, where he was CFO, responsible for all KOSDAQ listing-related matters. Mr. Kim holds his BA in Business Administration from Korea University and acquired his CPA license from Korea Institute of Certified Public Accountant.
Mr. Kim joined NeoImmuneTech, Inc. in May 2018 as Finance Director. His professional career began at PricewaterhouseCoopers (PwC) Korea in 2006. For 10+ years at PwC, he was mainly involved with financial audit services for Korean listed companies as a part of the Capital Market Group. Also, during his period at PwC, he successfully completed his secondment to another PwC territory, PwC Taiwan, for three years. This greatly increased his knowledge of Korean Capital Markets and overall global acumen. After that, he joined Englewood Lab, a New Jersey based company, and third US company listed on KOSDAQ, where he was CFO, responsible for all KOSDAQ listing-related matters. Mr. Kim holds his BA in Business Administration from Korea University and acquired his CPA license from Korea Institute of Certified Public Accountant.